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Abstract 
Background: The US Surgeon General’s Report on Bone Health suggests America’s 
bone-health is in jeopardy and issued a “call to action” to develop bone-health plans in-
corporating components of (1) improved nutrition, (2) increased health literacy, and (3) in-
creased physical activity.  
Objective:  To  conduct  a  Comparative  Effectiveness  Research  (CER)  study  comparing 
changes in bone mineral density in healthy women over-40 with above-average compliance 
when following one of three bone health Plans incorporating the SG’s three components. 
Methods: Using an open-label sequential design, 414 females over 40 years of age were 
tested, 176 of whom agreed to participate and follow one of three different bone-health 
programs. One Plan contained a bone-health supplement with 1,000 IUs of vitamin D3 and 750 
mg of a plant-sourced form of calcium for one year. The other two Plans contained the same 
plant form of calcium, but with differing amounts of vitamin D3 and other added bone health 
ingredients along with components designed to increase physical activity and health literacy. 
Each group completed the same baseline and ending DXA bone density scans, 43-chemistry 
blood test panels, and 84-item Quality of Life Inventory (QOL). Changes for all subjects were 
annualized as percent change in BMD from baseline. Using self-reports of adherence, subjects 
were rank-ordered and dichotomized as “compliant” or “partially compliant” based on the 
median rating. Comparisons were also made between the treatment groups and two theo-
retical age-adjusted expected groups: a non-intervention group and a group derived from a 
review of previously published studies on non-plant sources of calcium.  
Results: There were no significant differences in baseline BMD between those who volun-
teered versus those who did not and between those who completed per protocol (PP) and 
those who were lost to attrition. Among subjects completing per protocol, there were no 
significant differences between the three groups on baseline measurements of BMD, weight, 
age, body fat and fat-free mass suggesting that the treatment groups were statistically similar 
at baseline. In all three treatment groups subjects with above average compliance had sig-
nificantly greater increases in BMD as compared to the two expected-change reference 
groups. The group following the most nutritionally comprehensive Plan outperformed the 
other two groups. For all three groups, there were no statistically significant differences 
between baseline and ending blood chemistry tests or the QOL self-reports.  Int. J. Med. Sci. 2011, 8 
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Conclusions: The increases in BMD found in all three treatment groups in this CER stand in 
marked contrast to previous studies reporting that interventions with calcium and vitamin D3 
reduce age-related losses of BMD, but do not increase BMD. Increased compliance resulted in 
increased  BMD  levels.  No  adverse  effects  were  found  in  the  blood  chemistry  tests, 
self-reported quality of life and daily tracking reports. The Plans tested suggest a significant 
improvement over the traditional calcium and vitamin D3 standard of care. 
Key words: bone mineral density, bone-health supplement, women over-40 
Introduction 
In the 2010 update to its 2004-2009 Strategic Plan 
[1], NIH‟s Office of Dietary Supplements (ODS) en-
courages  research  assessing  the  effects  of  dietary 
supplements on biomarkers associated with chronic 
diseases, optimal health and improved performance. 
One major biomarker of ODS‟s goal was addressed in 
the  Surgeon  General’s  Report  on  Bone  Health  [2]  esti-
mating that by 2020 half of all American citizens over 
50 will be at risk of fractures due to poor bone health. 
The SG concluded that there is a bone health crisis in 
America due to increasingly sedentary lifestyles, ab-
sence of current information about bone health, and 
inadequate  nutrition.  The  SG  recommended  that 
people of all ages take  steps to improve their bone 
density (BMD) by ensuring that they are getting the 
recommended  amounts  of  calcium  and  vitamin  D3, 
and that supplementation may be helpful in meeting 
these nutritional goals. Based on findings in the Sur-
geon General’s Report on Bone Health, a “call to action” 
was issued for the development of bone health plans 
that  incorporate  three  components:  (1)  increased 
physical activity (2) improved health literacy, and (3) 
improved nutrition.  
In spite of the SG‟s “call to action”, calcium defi-
ciencies remain prevalent throughout the world [3] as 
well as in the US [4]. In addition to the persistence of 
sedentary lifestyles, poor nutritional habits, and lack 
of health literacy, there are other challenges to Amer-
ica‟s bone health that could benefit from supplemen-
tation.  The  increasing  number  of  the  elderly  is  ex-
tending the progressive age-related decline in BMD, 
thereby  increasing  the  need  for  additional  supple-
mental calcium and vitamin D3 [5]. There are concerns 
that current farming techniques are depleting the nu-
tritional composition of vitamins and minerals in our 
food  supply  [6-8].  A  wide  number  of  diseases  and 
medications  have  been  found  to  have  concomitant 
adverse  effects  on  bone  health  [9-13]  including  the 
increasing use of SSRIs for the treatment of depression 
[14-17] and contraceptives [18]. Since intentional and 
unintentional  weight  loss  typically  depletes  bone 
density [19-30] Americans obsession with dieting will 
increase  the  need  for  supplementation.  This  is  also 
true for the ten-fold increase in the number of bari-
atric  surgeries  performed  in  the  U.S.  to  combat  the 
adverse effects on bone health found associated with 
these surgeries [31,32]. In addition to the decline in 
bone health associated with sedentary lifestyles, ex-
cessive physical activity observed in athletes, partic-
ularly  young  athletes,  has  been  shown  to  have  ad-
verse effects on bone health, which could be improved 
with supplementation [33-34]. These factors suggest 
that the SG‟s 2004 call to action to develop safe and 
effective bone health plans is as relevant today as it 
was six years ago, and there is an extensive body of 
evidence  suggesting  supplementation  with  calcium 
and vitamin D3 could help reverse what the SG con-
cludes is a crisis in bone health. 
 Much of the evidence supporting the value of 
calcium  supplementation  is  summarized  in  an  ex-
haustive  meta-analysis  [5]  of  randomized  trials  in-
volving 63,897 subjects 50 years of age and older, most 
of whom were healthy postmenopausal women with 
an  average age  of 67.8  years.  The  meta-analysis  in-
cludes 23 trials of 41,419 subjects in which changes in 
BMD were the outcome measure, or one of the out-
come  measures.  No  studies  reported  that  supple-
mentation  worsened  age-related  declines  in  BMD. 
Nor were there any studies suggesting that supple-
mentation increased BMD over the study period. The 
overall finding was that with or without vitamin D3, 
calcium supplementation was associated with a “re-
duced rate of bone loss”.  
In view of these findings, studying another “me 
too” or “more of the same” product that also simply 
slows  BMD  loss  would  not  help  to  solve  the  bone 
health  crisis.  What  seemed  more  promising  was  a 
bone health plan with potential to halt, or even re-
verse,  age-related  BMD  loss-  a  goal  made  possible 
with the Comparative Effective Research (CER) mod-
el. As The American College of Physicians defines it, 
CER  studies  evaluate  the  relative  clinical  effective-
ness, safety, and cost of two or more medical services, 
drugs, devices, therapies, or procedures used to treat 
the same condition [35]. Without demonstrating the 
superiority  over  the  existing  standard  of  care  and Int. J. Med. Sci. 2011, 8 
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competing  interventions,  the  acceptability  of  an  in-
tervention becomes heavily dependent upon a com-
pany‟s marketing capability, as opposed to product 
superiority proven with safety and efficacy test results 
[36]. The emphasis of CER studies is to demonstrate 
the superiority of existing products and standards of 
care [37]. These types of studies span available inter-
ventions from pharmaceutical treatment, to lifestyle 
modifications  such  as  diet,  physical  activity,  and 
complementary and alternative therapies that are of-
ten initiated without physician input. But CER studies 
face publication challenges that need a paradigm shift 
in the scientific community to gain acceptance when 
competing  against  studies  using  placebo  or  control 
group protocols [38-41]. 
The purpose of this research was to conduct a 
CER  study  comparing  changes  in  baseline  BMD  in 
healthy  women  over  40  years  of  age  who  followed 
one of the three different bone health Plans shown in 
Table 1.  
Comparisons  were  also  made  with  two  refer-
ences groups of the same age and gender that were 
used to calculate expected changes, one without any 
form  of  intervention,  and  the  other  using  changes 
reported  in  studies  using  a  variety  of  non-plant 
sources of calcium.  
 
Table 1. Components/ingredients in the three bone-health plans 
 
 
Materials and Methods 
The protocol for Plans 2 and 3 were approved by 
the  RCRC  Institutional  Review  Board 
(www.RCRCIRB.com), Austin, TX, Protocol number 
1252006. The protocol for Plan 1 was approved by the 
researcher‟s ethics committee. Considerable effort was 
expended to recruit and enroll subjects using the same 
enrollment  procedures  in  order  to  facilitate  be-
tween-group  comparisons  on  relevant  outcome 
measures.  
Due  to  budget  restrictions,  instead  of  simulta-
neously enrolling a control group, the study sponsor 
chose to compare the three treatment groups effects 
with  a  pre-existing  annualized  expected  change  in 
BMD for women over 40 years of age, derived from 
data showing that after midlife there is an age-related 
yearly loss in both sexes of 1% [42] and an accelerated 
loss of up to 2% for 14 years for women of menopau-
sal  age  [43].  Additional  data  were  obtained  from 
norms provided by the DXA equipment manufacturer 
(GE Lunar), the researcher‟s database of over 26,000 
total body measurements, and from the National Os-
teoporosis  Foundation [44]. Based on these sources, 
we estimated a non-treatment effect of 0.75% per year. 
This  may  be  a  somewhat  conservative  estimate  in 
view  of  population-based  longitudinal  studies  sug-
gesting  that,  starting  at  age  40,  there  is  minor,  but 
significant,  annual  bone  loss  [45]  that  increases  to 
0.5% to 0.9% a year in perimenopausal women [46-49], 
to above 1% after menopause [48,49] after which the 
decline  remains  about  1%  [45,50,51].  Other  studies 
suggest after midlife there is an age-related yearly loss 
of bone in both sexes of 1% [52] which is accelerated to 
2% for up to 14 years in women around the age of 
menopause [53]. In men, a small loss is detected in 
40-year olds [45] that increases to a ~0.8% per year 
into old age [45,50-52]. More recently, another review 
has suggested that women will lose 35% to 39%, men 
17%-19%, of lifetime bone loss after achieving peak 
bone mass at ages 30-40 years [54], changes that are 
consistent with the previously cited studies.  
Another comparison was also made between the 
3 active treatment groups with a -0.1% expected an-
nualized  changes  in  BMD  when  taking  vitamin  D3 
and  non-plant  sources  of  calcium.  This  calculation Int. J. Med. Sci. 2011, 8 
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was made from studies cited in Tang et al.‟s [5] ex-
haustive  review  and  additional  data  provided  in 
studies [55-59] not cited in Tang et al.‟s review. The 
general conclusion from these studies is that supple-
mentation  with  calcium  and  vitamin  D  can  slow 
age-related declines in BMD, but none of these studies 
suggested  that  supplementation  can  increase  BMD 
levels.  
Improved  nutrition.  The  bone-health  supple-
ments in these plans were analyzed by Exova Labs, 
Chicago,  IL  for  confirmation  of  nutrient  levels  and 
absence of heavy minerals and other contaminating 
ingredients. Calcium, magnesium and other minerals 
were validated by Advanced Labs, Salt Lake City, UT.  
The  supplement  provided  to  all  study  groups 
contained a plant-sourced form of calcium with a re-
search  identity  of  DN0361  (commercially  known  as 
„AlgaeCal‟  or  „AC‟)  made  by  milling  whole, 
live-harvested sea algae found on the South American 
coastline. In addition to calcium, the algae contained 
other  naturally  occurring  minerals  in  the  following 
rank-order  of  percentage:  carbon,  chloride,  magne-
sium,  manganese,  selenium,  silicon,  sodium,  stron-
tium, titanium and vanadium, boron, silica, and cop-
per.  Many  of  these  minerals  have  been  reported  to 
play a role in bone health. A recent in-vitro study [60] 
demonstrated  superiority  over  the  two  most  com-
monly used calcium salts: calcium carbonate and cal-
cium citrate. Cultured human osteoblast cells (hFOB 
1.19) were treated with AC, calcium carbonate or cal-
cium citrate. Alkaline phosphatase activity was sig-
nificantly  increased  with  AC  treatment  when  com-
pared to control, calcium carbonate or calcium citrate 
(4.0, 2.0 and 2.5-fold, respectively). Proliferating cell 
nuclear  antigen  expression  (immunocytochemical 
analysis),  DNA  synthesis  (4.0,  3.0  and  4.0  fold,  re-
spectively) and Ca2+ deposition (2.0, 1.0 and 4.0 fold, 
respectively)  were  significantly  increased  in  AC 
treated  cells  when  compared  with  control,  calcium 
carbonate, or calcium citrate treatment. AC treatment 
significantly reduced oxidative stress when compared 
to calcium carbonate or calcium citrate (1.5, 1.4 fold, 
respectively).  This  earlier  study  demonstrated  that 
AC exhibited unique properties compared to calcium 
carbonate or calcium citrate on a cellular level, which 
suggests  the  need  for  human  intervention  studies 
such  as  the  present  study.  Furthermore,  safety  and 
toxicological investigations were conducted using AC 
and demonstrated its broad spectrum safety [61].  
Health  literacy.  To  provide  a  health  literacy 
component, with permission from the author, subjects 
following Plans 1 and 2 were provided with reprints 
from Chapters 5, 8, 9 &10 of a published book dealing 
with changes in body composition [62]. These chap-
ters provided information on bone density and on the 
pedometer-based  physical  activity  program.  Calorie 
estimation charts and glycemic load tables of over 300 
common  foods  designed  to  increase  the  quality  of 
carbohydrate intakes were also included [62]. Addi-
tional  health  awareness  was  gained  from  the  con-
sistent stream of feedback from the pedometer-based 
program described below. 
Physical Activity. To increase physical activity 
levels, subjects were asked to wear a pedometer dur-
ing their waking hours and to record and track their 
daily activity levels using the charts and graphs pro-
vided in their health literacy booklet. They were also 
asked to follow the instructions for personalizing the 
pedometer program to their personal goal weight. The 
Digi-Walker pedometer (HealthTech  Products, LLC, 
San  Antonio,  TX)  used  in  this  study  is  considered 
among  the  most  reliable  and  valid  of  pedometers 
available [63,64].  
Subjects. For all three plans, subjects were con-
tacted using the investigators‟ DXA (Total Body Du-
al-energy X-ray Absorptiometry) database, from par-
ticipants at a local health fair, and from referrals from 
subjects who agreed to participate. All subjects certi-
fied  that  they  had  reviewed  the  Informed  Consent 
with their personal healthcare provider or physician 
and that they had no medical conditions that would 
preclude their participation. However, pregnant and 
lactating  women  were  excluded  irrespective  of  this 
certification. Subjects were asked to refrain from tak-
ing other bone-health supplements during the study. 
In all three treatment groups, subjects and research 
technicians were blinded with regard to the subjects‟ 
baseline test results. For Plan 1, 60 adults completed a 
baseline  DXA  test,  58  agreed  to  participate  for  the 
one-year study period and 35 ultimately completed 
the study per-protocol (PP). For Plan 2, a total of 274 
S‟s were invited to complete a bone density test and to 
have the study components explained to them prior to 
enrolling for the study. Of these, 158 agreed to par-
ticipate, 125 of whom ultimately completed the study 
PP. For Plan 3, 80 adults were invited to complete a 
bone density test and to have study components ex-
plained to them prior to enrolling, 58 of whom agreed 
to participate and 51 completed the study PP. Figure 1 
shows a flow diagram through the study for the three 
study groups. 
To  encourage  candid  reporting  to  allow  for 
dose-related  and  compliance  comparisons,  all  en-
rolled  subjects  were  paid  a  “reporting  fee”  of 
$2.00/day  for  providing  daily  reports  of  their  sup-
plement usage and side effects. Throughout the study, 
subjects were repeatedly reminded that this fee was 
not an incentive for taking the product, but rather was Int. J. Med. Sci. 2011, 8 
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for the purpose of encouraging candid reporting to 
allow for analyses of the effects of adherence. Subjects 
were also advised that the reporting fees would be 
paid irrespective of product usage as long as the par-
ticipant  completed  all  ending  tests.  This  procedure 
was also designed to provide an additional measure 
of product efficacy on the assumption that if a plan 
was  efficacious,  compliant  subjects  should  outper-
form partially compliant subjects. 
 
 
 
 
Figure 1. Flow of participants through the three study legs 
 
 
Outcome  Measure  of  efficacy.  Although  the 
primary outcome measure for all three study groups 
was changes in BMD among highly compliant sub-
jects when following each of the three plans, data was 
also reported for the entire cohort for each Plan. BMD 
was  assessed  by  dual-energy  X-ray  absorptiometry 
(DXA) total body scans (GE Lunar, LUNAR Corpora-
tion,  Madison,  WI,  USA).  Longitudinal  precision  of 
the  DXA  unit  was  monitored  using  repeated 
measures of total bone density phantoms provided by 
the manufacturer.  
Outcome Measure of safety. To assess safety in 
all three Plans at baseline and at the end of the study 
period, subjects completed the 50-item Quality of Life 
inventory [64] shown in Table 2, the 43-item blood 
chemistry panel shown in Table 3, and daily tracking 
self-reports  on  positive/negative  reactions  to  the 
product and product usage.  
Compliance.  In  order  to  obtain  a  compliance 
rating (since poor compliance is a major obstacle to 
obtaining the full benefit of bone-health supplements) 
[5], the research technician who had the most frequent 
contact with S‟s (subjects) rated the subjects‟ compli-
ance  with  the  protocol  using  a  5-point  scale.  Each 
group was then rank-ordered and dichotomized at the 
median.  When  making  these  ratings  and  classifica-
tions, both the technician and the investigator were 
blinded with respect to the subject‟s BMD measure-
ments.  Those  above  the  median  were  classified  as 
“compliant”, and those below the median were clas-
sified as “partially compliant.”  
Statistical Methods 
Since the study period for Plan 1 was one year 
and the study period was six-months for Plans 2 and 
3, BMD changes and comparisons were reported as 
mean  annualized  percent  change  (MPAC).  Annual-
izing changes also allowed easier comparisons with 
other studies reported in the literature.. Continuously 
distributed data were summarized with the mean and 
standard  deviation;  binary  outcomes  were  summa-
rized with counts and percents. Study groups were 
contrasted  on  MAPC  (Mean  Annualized  Percent 
Change  in  BMD)  with  analyses  of  covariance  with 
adjustment for age and sex. Group contrasts with re-
gard to binary outcomes were made with Pearson‟s 
chi-square. All statistical testing was 2-sided with a 
significance level of 5%. SAS Version 9.1.3 for Win-
dows (SAS Institute, Cary, North Carolina) was used 
throughout.  
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Table 2. Quality of Life Inventory 
 
 
 
Table 3. Listing of Blood Chemistries 
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Results  
 
All subjects. As shown in the baseline charac-
teristics in Table 4, with the exception of the higher 
level of body fat in subjects following Plan 1 vs. Plan 
2, there were no significant differences between the 
three groups in baseline BMD or in the 4 variables 
related  to  BMD,  thus  suggesting  that  the  treatment 
groups  were  statistically  similar  in  spite  of  the  se-
quential  enrollment  of  subjects.  There  also  were  no 
differences on these baseline demographics between 
subjects who chose not to enroll and those who com-
pleted  PP,  or  between  those  who  enrolled,  but 
dropped out, as compared to those who completed 
PP.  Subjects  in  all  three  plans  had  an  increase  in 
MAPC: Plan 1=1.20%, Plan 2=0.33%, and Plan 3=2.5%. 
Using a repeated measures t-test, MAPC in Plan 1 and 
3 were significant (P=0.027 and P=0.002 respectively), 
but the MAPC in Plan 2 failed to reach significance 
(P=0.430). However, the MAPC in all three Plans was 
significant  when  compared  to  the  expected-change 
non-intervention normative group (P<0.001) and the 
reference  group  derived  from  a  literature  review 
(P<0.001, P=0.026, and P<0.001 respectively.) 
Compliant sub-groups. As shown in the base-
line characteristics in Table 5, with the exception of 
the  higher  BMD  in  Plan  3  as  compared  to  Plan  1 
(P=0.025), and the higher scale weight in Plan 2 versus 
Plan 3, there were no significant differences between 
the baseline demographics for the three groups, sug-
gesting that they were reasonably similar at baseline. 
Among the compliant sub-group, there also was no 
significant  differences  on  these  baseline  de-
mographics between subjects who chose not to enroll 
and those who completed PP, or between those who 
enrolled,  but  dropped,  as  compared  to  those  who 
completed PP. 
 
Table 4. Means and between-group t-tests of baseline demographic measures for subjects following one of the three 
bone-health plans. 
 
Table 5. Means and between-group t-tests of baseline demographic measures for compliant sub-groups in each of the three 
Plans. 
 
 
 
 
As  shown  in  Figure  2,  subjects  following  all 
three plans had an increase in MAPC: Plan 1=1.30%, 
Plan  2=2.00%,  and  Plan  3=4.1%.  Using  a  repeat-
ed-measures  t-test,  the  MAPC  from  baseline  in  all 
three  Plans  was  significant  (P=0.003,  P=<0.001,  and 
P=0.003, respectively). The MAPC in Plan 3 was sig-
nificantly greater than Plan 1 (P=0.002), but was not 
significantly greater than Plan 2 (P=0.262) nor was the 
difference between Plan 1 and Plan 2 (P=0.063). Alt-
hough not shown in Figure 2 since we had no com-
pliance  data  on  the  two  expected  change  groups, 
comparisons between the three Plans and all subjects 
in  both  expected  change  groups  revealed  that  the 
MAPC  in  all  three  Plans  was  significantly  greater 
(P<0.001) than both of these groups.  
 With  regard  to  the  QOL  shown  previously  in 
Table  2,  there  were  no  significant  baseline/ending 
changes in any of the 50 items or in a total QOL score 
(the sum of all 50 items). Assessment of safety using 
the QOL is straight-forward. An increase in the total Int. J. Med. Sci. 2011, 8 
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scale or individual item scores suggests increased risk 
and potential adverse effects. Similarly, evaluation of 
changes  in  cholesterol,  LDL,  Triglycerides, 
HDL/Total ratio, glucose, and C-reactive protein; and 
decreases  in  HDL  suggest  a  negative  outcome  and 
potential  adverse  reaction.  In  all  three  Plans,  there 
were  no  statistically  significant  changes  in  any  of 
these  “uni-directional”  test  scores.  However,  evalu-
ating changes in the remaining 37 chemistries is less 
straight  forward  since  they  are  “multi-directional” 
where both increases or decreases could be associated 
with either positive or negative outcomes. Addition-
ally, with the remaining 37 chemistries, it is probable 
that  some  changes  could  be  statistical  artifacts. 
Therefore, instead of using changes from baseline in 
all  37  chemistries,  we  compared  the  number  of 
changes in scores that were in the normal or accepta-
ble ranges at baseline with those that became abnor-
mal or unacceptable by the end of the study. In all 
three  groups  and  sub-groups,  none  of  the  normal 
scores were abnormal by the end of the study. Thus, it 
was our conclusion that the absence of changes in the 
unit-  and  multi-directional  blood  chemistries  sup-
ports the safety of the Plans.  
 
 
 
 
Figure 2. Within- and between-groups comparisons of annualized changes in Bone Mineral Density (BMD) in women over 
40 who followed one of three different bone-health treatment plans and who were rated in the upper 50%-ile of protocol 
compliance. P levels on the diagonal represent changes from baseline using within-group repeated measures t-tests. 
 
 
Discussion 
This  CER  study  was  designed  to  compare  the 
safety and efficacy of three bone health Plans using 
three  independent  sequentially  enrolled  groups  of 
healthy women 40 years of age and older. The pri-
mary outcome measure was changes in baseline BMD 
(Bone  Mineral  Density)  among  participants  with 
above  average  compliance  in  order  to  examine  the 
safety and efficacy in people complying with the bone 
health plans as designed. However, additional anal-
yses were also conducted using all subjects in each of 
the three study cohorts. Within-group comparisons of 
changes  in  BMD  from  baseline  and  between-group 
comparisons with the two different expected change 
reference groups support the safety and efficacy of all Int. J. Med. Sci. 2011, 8 
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three Plans. It is also noteworthy that all three bone 
health plans facilitated outright increases in BMD, a 
finding that stands in marked contrast to a plethora of 
studies suggesting that calcium and vitamin D3 sup-
plementation  can,  at  best,  only  slow  down  the 
age-related decline in BMD.  
Notwithstanding the evidence presented in this 
study, one could conclude that the increased MAPC 
from baseline and over-expected was attributable to 
using  a  sequential  design  with  subject  groups  with 
unequal  baseline  demographic  characteristics.  The 
absence of a placebo-controlled arm raises concerns 
about placebo effects. Questions may also be raised 
about the validity of the two expected change refer-
ence groups to which changes in BMD in the three 
Plans were compared. Furthermore, the reported in-
crease, instead of slowing, of BMD attributable to the 
three bone health plans stands in marked contrast to 
previous research and warrants further comment.  
With  regard  to  the  equivalence  of  the  groups, 
while it is impossible to rule out all potentially con-
founding variables, increased confidence in the simi-
larity of the three groups was obtained from a com-
parison  of  baseline  demographic  measures  of  the 
groups that found, in general, no statistical differences 
between the groups in BMDs or in variables affecting 
BMD (weight, gender, lean mass, % fat, and BMI), in 
any  of  the  43  baseline  blood  chemistries,  or  in  the 
QOL analyses. In all three groups, there were no dif-
ferences  in  baseline  demographics  between  volun-
teers and non-volunteers, or between those subjects 
who completed versus those who dropped out. Taken 
together, these similarities provide considerable evi-
dence that the three groups were reasonably equiva-
lent. 
 With regard to placebo effects, it seems implau-
sible to suggest that the reported positive changes in 
BMD  were  the  result  of  placebo  effects,  when  the 
placebo groups in almost all pharmaceutical and nu-
tritional interventions lost BMD. For example, three 
randomized double-blinded placebo-controlled stud-
ies measuring the effects of strontium ranelate [65-67] 
found a progressive and linear decrease in BMD in 
placebo groups for each of the three study years--a 1% 
annual  decline  which  was  virtually  identical  to  the 
age-gender  adjusted  expected  changes  used  in  this 
study. In contrast to the absence of studies on placebo 
effects on BMD, a number of studies have suggested 
that consumption of the multiple nutrients in the AC 
formulas could facilitate increases in BMD [68]. Con-
siderable  evidence  is  available  on  the  bone-health 
effects  of  the  nutrients  in  the  AlgaeCal  formu-
la--supplemental  magnesium,  vitamin  K-2,  calcium 
and Vitamin D3 [69-70]. Vitamin C has also been re-
ported as an essential nutrient for collagen formation 
and normal bone development, particularly in older 
men and women [71-72].  
With regard to the validity of the two expected 
change  reference  groups,  in  the  non-intervention 
group, the estimate for an annual  -0.75% decline in 
BMD appears conservative. The women in this study 
had an average age of 57.4 (41-89) which is consistent 
with the age-related decline of 1% to 2% cited above 
for women of menopausal age as well as with the data 
reported in the meta-analysis. As for the estimate for 
expected  changes  in  BMD  from  traditional  calcium 
supplementation found  in the literature review, the 
annual decline of 0.10% is also conservative based on 
the  studies  we  reviewed  as  well  as  the  studies  re-
viewed in the meta-analysis cited above.  
As for the unusual finding of the increased BMD 
levels found in the three study groups, the superiority 
of Plan 3 over Plan 1 suggests that the physical activ-
ity and health literacy components may have made 
contributions beyond the effects of supplementation 
alone. As for BMD increases in Plan 1, without these 
components, and without definitive data, some of the 
explanation may be attributed to what appears to be 
optimal levels of vitamin D3 (1,000 IU) and calcium 
(750 mg) that were in the Plan 1 version of AC. An 
additional benefit may be attributed to the use of a 
plant-sourced  form  of  calcium  that,  as  discussed 
above,  appears  to  be  more  bio-available  than  more 
traditional forms of calcium. Additionally, there are 
studies  [68,73-78]  supporting  the  suggestion  that 
plant-sourced minerals may be more easily absorbed 
than  non-plant-sourced  calcium  and  minerals,  and 
that the body is able to use less than 10 percent of the 
minerals  contained  in  the  most  popular  brands  of 
multivitamins, as opposed to over 80 percent of min-
erals derived from plant sources. Other studies have 
also reported positive associations between fruit and 
vegetable  consumption  and  BMD  in  elderly  adults 
[77-79],  adolescents  [80]  and  children  [81].  Another 
potential  explanation  is  that,  although  total  body 
BMD  is  highly  correlated  with  spinal  and  femur 
measurements,  the  total  body  measurement  is  less 
affected by the more subjective judgments made with 
spine and femur. In contrast to total body measure-
ments where the operator needs only to position the 
patient on the scanning table, but does not need to 
make  the  more  subjective  decisions  regarding  the 
spinal lumbar and femoral regions.  
Conclusions 
This study found that following any of the three 
Plans was associated with increases in BMD as op-
posed to merely slowing down the decline in BMD, Int. J. Med. Sci. 2011, 8 
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which had been the general conclusions from a wide 
range of studies on the efficacy of vitamin D and cal-
cium  supplementation.  These  increases  occurred 
without  adverse  side  effects.  While  the  study  also 
provides evidence of the benefit of adding the physi-
cal activity and health literacy components, the data 
also support the efficacy of plant-source calcium as a 
stand-alone product.  
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